BE889150A - Derives hydroxycarboxyles du compose ml-236b, leur procede de preparation et leur application therapeutique - Google Patents

Derives hydroxycarboxyles du compose ml-236b, leur procede de preparation et leur application therapeutique

Info

Publication number
BE889150A
BE889150A BE0/205046A BE205046A BE889150A BE 889150 A BE889150 A BE 889150A BE 0/205046 A BE0/205046 A BE 0/205046A BE 205046 A BE205046 A BE 205046A BE 889150 A BE889150 A BE 889150A
Authority
BE
Belgium
Prior art keywords
hydroxycarboxyl
derivatives
compound
preparation process
therapeutic application
Prior art date
Application number
BE0/205046A
Other languages
English (en)
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27465909&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE889150(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from JP7612780A external-priority patent/JPS572240A/ja
Priority claimed from JP11548380A external-priority patent/JPS57108039A/ja
Priority claimed from JP12438580A external-priority patent/JPS5750894A/ja
Priority claimed from JP13031180A external-priority patent/JPS5767575A/ja
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of BE889150A publication Critical patent/BE889150A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/145—Fungi isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02—Oxygen as only ring hetero atoms
    • C12P17/06—Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/62—Carboxylic acid esters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465—Streptomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/645—Fungi ; Processes using fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/645—Fungi ; Processes using fungi
    • C12R2001/65—Absidia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/645—Fungi ; Processes using fungi
    • C12R2001/785—Mucor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/645—Fungi ; Processes using fungi
    • C12R2001/845—Rhizopus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/886—Streptomyces

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
BE0/205046A 1980-06-06 1981-06-09 Derives hydroxycarboxyles du compose ml-236b, leur procede de preparation et leur application therapeutique BE889150A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP7612780A JPS572240A (en) 1980-06-06 1980-06-06 Ml-236b derivative
JP11548380A JPS57108039A (en) 1980-08-22 1980-08-22 Ml-236b derivative
JP12438580A JPS5750894A (en) 1980-09-08 1980-09-08 Preparation of ml-236b derivative
JP13031180A JPS5767575A (en) 1980-09-19 1980-09-19 Ml-236b derivative

Publications (1)

Publication Number Publication Date
BE889150A true BE889150A (fr) 1981-12-09

Family

ID=27465909

Family Applications (1)

Application Number Title Priority Date Filing Date
BE0/205046A BE889150A (fr) 1980-06-06 1981-06-09 Derives hydroxycarboxyles du compose ml-236b, leur procede de preparation et leur application therapeutique

Country Status (17)

Country Link
US (3) US4346227A (fr)
AT (1) AT374495B (fr)
AU (1) AU549988B2 (fr)
BE (1) BE889150A (fr)
CA (1) CA1150170A (fr)
CH (1) CH655090A5 (fr)
DE (1) DE3122499A1 (fr)
DK (1) DK149080C (fr)
ES (1) ES502827A0 (fr)
FI (1) FI71168C (fr)
FR (1) FR2483912B1 (fr)
GB (1) GB2077264B (fr)
IE (1) IE51270B1 (fr)
IT (1) IT1144598B (fr)
MX (1) MX7065E (fr)
NL (2) NL191738C (fr)
SE (1) SE453389B (fr)

Families Citing this family (531)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
JPS56150037A (en) 1980-04-22 1981-11-20 Sankyo Co Ltd Hydronaphthalene compound
US4432996A (en) * 1980-11-17 1984-02-21 Merck & Co., Inc. Hypocholesterolemic fermentation products and process of preparation
JPS57185275A (en) * 1981-05-07 1982-11-15 Sankyo Co Ltd Tetrahydro-dum-4 and tetrahydro-isodum-4 and their derivatives
JPS57185276A (en) * 1981-05-11 1982-11-15 Sankyo Co Ltd Dihydro-dum-4 and dihydro-isodum-4 and their derivative
JPS5815968A (ja) * 1981-07-21 1983-01-29 Sankyo Co Ltd Ｍｌ−２３６ｂ誘導体およびその製法
JPS5835144A (ja) * 1981-08-27 1983-03-01 Sankyo Co Ltd Ｍｂ−５３０ｂ誘導体およびその製造法
JPS5889191A (ja) * 1981-11-20 1983-05-27 Sankyo Co Ltd ３−ヒドロキシ−ｍｌ−２３６ｂ誘導体の製造法
PH20405A (en) * 1983-07-21 1987-01-05 Fujisawa Pharmaceutical Co Anti-tumor agent container fr.900216 substance or its pharmaceutically acceptable salts thereof
EP0164049B1 (fr) * 1984-06-04 1990-12-12 Merck & Co. Inc. Procédé de préparation d'inhibiteurs de la HMG-CoA réductase contenant un élément 3,5-dihydroxypentanoique
US4611068A (en) * 1984-11-19 1986-09-09 Merck Frosst Canada, Inc. Process for the preparation of HMG-CoA reductase inhibitors and intermediate compounds employed therein
EP0204287A3 (fr) * 1985-06-04 1987-07-01 Merck & Co. Inc. Procédé de préparation d'inhibiteurs de la HMG-CoA réductase ayant des sous-groupes 3,5-dihydroxy pentanoiques
USRE33033E (en) * 1985-07-05 1989-08-22 Merck & Co., Inc. Process for the preparation of HMG-CoA reductase inhibitors intermediates
US4611081A (en) * 1985-07-05 1986-09-09 Merck & Co., Inc. Process for the preparation of HMG-CoA reductase inhibitors intermediates
US4668699A (en) * 1985-08-05 1987-05-26 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US5272174A (en) * 1985-09-13 1993-12-21 Sankyo Company, Limited Hydroxy-ML-236B derivatives, their preparation and use
ATE69602T1 (de) * 1985-09-13 1991-12-15 Sankyo Co Hydroxy-ml-236b-derivate, deren herstellung und anwendung.
JPH0633312B2 (ja) * 1986-05-02 1994-05-02 大正製薬株式会社 １４−ハイドロキシエリスロマイシン誘導体およびその製造方法
US4864038A (en) * 1986-05-05 1989-09-05 Merck & Co., Inc. Antihypercholesterolemic compounds
US4766145A (en) * 1986-05-05 1988-08-23 Merck & Co., Inc. Antihypercholesterolemic compounds
US4771071A (en) * 1986-05-05 1988-09-13 Merck & Co., Inc. Antihypercholesterolemic compounds
US4937264A (en) * 1986-05-05 1990-06-26 Merck & Co., Inc. Antihypercholesterolemic compounds
EP0245990A3 (fr) * 1986-05-05 1989-07-19 Merck & Co. Inc. Composés antihypercholestérolémiques
EP0245004A3 (fr) * 1986-05-05 1989-07-26 Merck & Co. Inc. Composés antihypercholestérolémiques
EP0245003A3 (fr) * 1986-05-05 1989-07-19 Merck & Co. Inc. Composés antihypercholestérolémiques
US4661483A (en) * 1986-05-05 1987-04-28 Merck & Co., Inc. Antihypercholesterolemic lactone compounds, compositions and use
US4847306A (en) * 1986-05-05 1989-07-11 Merck & Co., Inc. Antihypercholesterolemic compounds
US4940727A (en) * 1986-06-23 1990-07-10 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US5116870A (en) * 1986-06-23 1992-05-26 Merck & Co., Inc. HMG-CoA reductase inhibitors
USRE36481E (en) * 1986-06-23 2000-01-04 Merck & Co., Inc. HMG-CoA reductase inhibitors
AU1422388A (en) * 1987-01-27 1988-08-10 Warner-Lambert Company Lipid regulating compositions
US4833258A (en) * 1987-02-17 1989-05-23 Merck & Co., Inc. Intermediates useful in the preparation of HMG-COA reductase inhibitors
DE3869282D1 (de) * 1987-09-02 1992-04-23 Merck & Co Inc Inhibitoren von hmg-coa-reduktase.
US4997848A (en) 1987-10-27 1991-03-05 Sankyo Company, Limited Octahydronaphthalene oxime derivatives for cholesterol synthesis inhibition
US4857547A (en) * 1988-01-07 1989-08-15 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US5021453A (en) * 1988-03-02 1991-06-04 Merck & Co., Inc. 3-keto HMG-CoA reductase inhibitors
US5155229A (en) * 1988-03-21 1992-10-13 E. R. Squibb & Sons, Inc. Derivatives of pravastatin and method of making the same
US4857522A (en) * 1988-03-21 1989-08-15 E. R. Squibb & Sons, Inc. Derivatives of pravastatin for inhibiting cholesterol biosynthesis
US5047549A (en) * 1988-03-21 1991-09-10 E. R. Squibb & Sons, Inc. Derivatives of pravastatin for inhibiting cholesterol biosynthesis
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
US5180589A (en) * 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
US4997755A (en) * 1988-04-15 1991-03-05 Merck & Co., Inc. HMG-CoA reductase inhibitors produced by Nocardia sp. (MA 6455)
US4963538A (en) * 1988-06-29 1990-10-16 Merck & Co., Inc. 5-oxygenated HMG-CoA reductase inhibitors
US5075327A (en) * 1988-08-10 1991-12-24 Hoffmann-La Roche Inc. Antipsoriatic agents
US5021451A (en) * 1988-11-14 1991-06-04 Hoffman-La Roche Inc. Method for inhibiting hyperproliferative diseases
US5073568A (en) * 1988-11-14 1991-12-17 Hoffmann-La Roche Inc. Antipsoriatic agents
US5200549A (en) * 1988-11-14 1993-04-06 Hoffman-La Roche Inc. Antipsoriatic agents
US5376383A (en) * 1988-11-21 1994-12-27 Merck & Co., Inc. Method for enhancing the lowering of plasma-cholesterol levels
US5260305A (en) * 1988-12-12 1993-11-09 E. R. Squibb & Sons, Inc. Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination
JP2763782B2 (ja) * 1989-02-14 1998-06-11 旭電化工業株式会社 メバロン酸の製造方法
US5166364A (en) * 1989-02-27 1992-11-24 E. R. Squibb & Sons, Inc. Mevinic acid derivatives useful as antihypercholesterolemic agents and method for preparing same
CA2016467A1 (fr) 1989-06-05 1990-12-05 Martin Eisman Methode de traitement de l'atherosclerose des vaisseaux peripheriques a l'aide d'un inhibiteur de l'hmg coa reductase et (ou) d'un inhibiteur de la squalene synthetase
US5001148A (en) * 1989-06-07 1991-03-19 E. R. Squibb & Sons, Inc. Mevinic acid derivatives
US5102911A (en) * 1989-06-09 1992-04-07 Merck & Co, Inc. 4-Substituted HMG-CoA reductase inhibitors
US4970231A (en) * 1989-06-09 1990-11-13 Merck & Co., Inc. 4-substituted HMG-CoA reductase inhibitors
US5041562A (en) * 1989-06-09 1991-08-20 Merck & Co., Inc. 3-keto HMG-CoA reductase inhibitors
US4937259A (en) * 1989-06-09 1990-06-26 Merck & Co., Inc. Antihypercholesterolemic compounds
US5001241A (en) * 1989-06-09 1991-03-19 Merck & Co., Inc. 3-KETO HMG-CoA reductase inhibitors
US5010105A (en) * 1989-06-09 1991-04-23 Merck & Co., Inc. Antihypercholesterolemic compounds
US4965200A (en) * 1989-06-23 1990-10-23 Merck & Co., Inc. Process for the preparation of 3-keto, 5-hydroxy simvastatin analogs
US4997849A (en) * 1989-06-23 1991-03-05 Merck & Co., Inc. Microbial transformation of simvastatin
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5316765A (en) * 1989-09-07 1994-05-31 Karl Folkers Foundation For Biomedical And Clinical Research Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies
US5212296A (en) * 1989-09-11 1993-05-18 E. I. Du Pont De Nemours And Company Expression of herbicide metabolizing cytochromes
US5173487A (en) * 1989-11-13 1992-12-22 E. R. Squibb & Sons, Inc. Mevinic acid derivatives
US5177104A (en) * 1990-04-03 1993-01-05 E. R. Squibb & Sons, Inc. 6-α-hydroxy derivatives of mevinic acids
GB9007738D0 (en) * 1990-04-05 1990-06-06 British Bio Technology Compounds
US5089523A (en) * 1990-05-11 1992-02-18 E. R. Squibb & Sons, Inc. Fluorinated derivatives of mevinic acids
US6630502B2 (en) 1990-05-15 2003-10-07 E.R. Squibb & Sons, Inc. Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
US5140012A (en) * 1990-05-31 1992-08-18 E. R. Squibb & Sons, Inc. Method for preventing onset of restenosis after angioplasty employing pravastatin
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
US5264455A (en) * 1990-07-06 1993-11-23 E. R. Squibb & Sons, Inc. Sulfur-substituted mevinic acid derivatives
US5223415A (en) * 1990-10-15 1993-06-29 Merck & Co., Inc. Biosynthetic production of 7-[1',2',6',7',8',8a'(R)-hexahydro-2'(S),6'(R)-dimethyl-8'(S)-hydroxy-1'(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid)
IE75349B1 (en) * 1991-03-07 1997-08-27 Lonza Ag A process for the terminal hydroxylation of ethyl groups on aromatic 5- or 6-membered heterocyclic compounds
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
US5286746A (en) * 1991-12-20 1994-02-15 E. R. Squibb & Sons, Inc. Sulfur-substituted mevinic acid derivatives
US5620876A (en) * 1992-04-29 1997-04-15 E. R. Squibb & Sons, Inc. Enzymatic hydrolysis and esterification processes for the preparation of HMG-CoA reductase inhibitors and intermediates thereof
FI932188L (fi) 1992-05-15 1993-11-16 Sankyo Co Oktahydronaftalenoximderivat foer inhibering av kolesterolbiosyntesen, deras framstaellning och anvaendning
US5369123A (en) * 1992-10-09 1994-11-29 E. R. Squibb & Sons, Inc. Nitrogen-substituted mevinic acid derivatives useful as HMG-CoA reductase inhibitors
NZ250609A (en) * 1992-12-28 1995-07-26 Sankyo Co Hexahydronaphthalene esters and ring closed lactones; preparation and medicaments
IL108432A (en) * 1993-01-29 1997-09-30 Sankyo Co DERIVATIVES OF 3, 5-DIHYDROXY-7- £1, 2, 6, 7, 8, 8a-HEXAHYDRO-2- METHYL-8- (SUBSTITUTED ALKANOYLOXY)-1-NAPHTHYL| HEPTANOIC ACID AND THEIR LACTONES, THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2709126B1 (fr) * 1993-08-18 1995-09-29 Adir Nouveaux dérivés de naphtalène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US6043064A (en) * 1993-10-22 2000-03-28 Bristol-Myers Squibb Company Enzymatic hydroxylation process for the preparation of HMG-CoA reductase inhibitors and intermediates thereof
JPH09504436A (ja) * 1993-11-02 1997-05-06 メルク エンド カンパニー インコーポレーテッド トリオールポリケチドシンターゼをコードするｄｎａ
WO1995013063A1 (fr) * 1993-11-09 1995-05-18 Merck & Co., Inc. Inhibiteurs de l'hmg-coa reductase dans la normalisation des troubles de l'endothelium vasculaire
US6369103B1 (en) * 1994-01-18 2002-04-09 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
US5681278A (en) * 1994-06-23 1997-10-28 Cormedics Corp. Coronary vasculature treatment method
US6268392B1 (en) 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US6262277B1 (en) * 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US5616595A (en) * 1995-06-07 1997-04-01 Abbott Laboratories Process for recovering water insoluble compounds from a fermentation broth
US5942423A (en) 1995-06-07 1999-08-24 Massachusetts Institute Of Technology Conversion of compactin to pravastatin by actinomadura
US5900433A (en) * 1995-06-23 1999-05-04 Cormedics Corp. Vascular treatment method and apparatus
US5798375A (en) * 1995-07-03 1998-08-25 Sankyo Company, Limited Treatment of arteriosclerosis and xanthoma
KR100186758B1 (ko) * 1996-08-09 1999-04-01 영진약품공업 주식회사 프라바스타틴(pravastatin)전구체의제조방법
AU727895B2 (en) * 1997-01-17 2001-01-04 Bristol-Myers Squibb Company Method for treating atherosclerosis with an MPT inhibitor and cholesterol lowering drugs
US6066653A (en) * 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
KR100210482B1 (ko) * 1997-04-10 1999-07-15 김종인 스트렙토마이세스엑스포리아투스(streptomycesexfoliatus)yj-118과이를이용한프라바스타틴나트륨의제조방법
EP0877089A1 (fr) 1997-05-07 1998-11-11 Gist-Brocades B.V. Procédé de préparation pour un inhibiteur de Hmg-Coa réductase
US20010006644A1 (en) 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
JP4162848B2 (ja) 1997-08-07 2008-10-08 協和醗酵工業株式会社 ＨＭＧ−ＣｏＡレダクターゼ阻害剤の製造法
AU9264598A (en) * 1997-08-22 1999-03-16 Gist-Brocades B.V. Statin production by fermentation
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
US6177121B1 (en) 1997-09-29 2001-01-23 Purdue Research Foundation Composition and method for producing low cholesterol eggs
US6147109A (en) * 1997-10-14 2000-11-14 The General Hospital Corporation Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
US6083497A (en) 1997-11-05 2000-07-04 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
US20080275104A1 (en) * 1997-11-25 2008-11-06 Musc Foundation For Research Development Methods of treating juvenile type 1 diabetes mellitus
US20040029962A1 (en) * 1997-12-12 2004-02-12 Chih-Ming Chen HMG-COA reductase inhibitor extended release formulation
US20060141036A1 (en) * 1997-12-12 2006-06-29 Andrx Labs Llc HMG-CoA reductase inhibitor extended release formulation
US6180597B1 (en) 1998-03-19 2001-01-30 Brigham And Women's Hospital, Inc. Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors
SI9800144A (sl) 1998-05-21 1999-12-31 LEK, tovarna farmacevtskih in kemičnih izdelkov, d.d. Nov biotehnološki postopek pridobivanja 3-hidroksi-ML-236B derivatov poznanih kot M-4 in M-4'
WO1999067809A1 (fr) 1998-06-24 1999-12-29 Merck & Co., Inc. Compositions et procedes inhibant la resorption osseuse
US20030078211A1 (en) * 1998-06-24 2003-04-24 Merck & Co., Inc. Compositions and methods for inhibiting bone resorption
US6423751B1 (en) 1998-07-14 2002-07-23 The Brigham And Women's Hospital, Inc. Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
US5985907A (en) * 1998-08-12 1999-11-16 Health Research, Inc. Method for inhibiting growth of methanogens
SI20305A (sl) * 1999-08-06 2001-02-28 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristali natrijeve soli pravastatina
SI20070A (sl) * 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Nove soli inhibitorjev HMG-CoA reduktaze
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US20080213378A1 (en) * 1998-10-01 2008-09-04 Elan Pharma International, Ltd. Nanoparticulate statin formulations and novel statin combinations
US7939105B2 (en) 1998-11-20 2011-05-10 Jagotec Ag Process for preparing a rapidly dispersing solid drug dosage form
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
US6391583B1 (en) * 1998-12-18 2002-05-21 Wisconsin Alumni Research Foundation Method of producing antihypercholesterolemic agents
EP1342475A1 (fr) 1998-12-23 2003-09-10 G.D. Searle LLC. Combinaisons d'inhibiteurs de transport de l'acide biliaire iléal et d'inhibiteurs de la protéine de transfert de l'ester de cholestéryle utilisées dans le cadre de maladies cardio-vasculaires
CN1342091A (zh) * 1998-12-23 2002-03-27 G.D.瑟尔有限公司 心血管指征的联合用药
AU2157400A (en) 1998-12-23 2000-07-31 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications
EP1140186B1 (fr) * 1998-12-23 2003-06-04 G.D. Searle LLC. Combinaisons d'inhibiteurs de la proteine de transfert de l'ester de cholesteryle et de derives de l'acide fibrique utilisees dans le cadre de troubles cardio-vasculaires
MXPA01006472A (es) * 1998-12-23 2004-03-10 Searle Llc Combinaciones de inhibidores de transporte de acido biliar ileal y derivados de acido fibrico para indicaciones cardiovasculares.
DK1140185T3 (da) 1998-12-23 2003-09-29 Searle Llc Kombinationer af cholesterylestertransferhæmmere og galdesyre kompleksdannende forbindelser til hjertekar indikationer
DK1140184T3 (da) 1998-12-23 2003-09-29 Searle Llc Kombinationer af cholesterylestertransferproteinhæmmere og nikotinsyrederivater til hjertekar indikationer
PT1140190E (pt) 1998-12-23 2003-02-28 Searle Llc Combinacoes de inibidores do transporte ileal dos acidos biliares e agentes sequestrantes dos acidos biliares usadas para problemas cardiovasculares
EP1146126B1 (fr) 1999-01-20 2007-04-25 Kyowa Hakko Kogyo Co., Ltd. Procede de production d'inhibiteurs de la hmg coa-reducatase
KR20010108139A (ko) * 1999-01-29 2001-12-07 히라타 다다시 히드록시메틸글루타릴 코에이 환원효소 저해제의 제조방법
US6682913B1 (en) 1999-02-03 2004-01-27 Institute For Drug Research Ltd. Microbial process for preparing pravastatin
US6569461B1 (en) * 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
HUP9902352A1 (hu) * 1999-07-12 2000-09-28 Gyógyszerkutató Intézet Kft. Eljárás pravasztatin mikrobiológiai előállítására
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
HUP0203326A3 (en) * 1999-08-30 2003-04-28 Sanofi Aventis Deutschland Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
US6444452B1 (en) 1999-11-30 2002-09-03 Biogal Gyogyszergyar Rt. Process for recovering statin compounds from a fermentation broth
CZ20021998A3 (cs) * 1999-12-14 2003-02-12 Biogal Gyogyszergyar Rt. Nové formy sodné soli pravastatinu
IN191580B (fr) * 1999-12-17 2003-12-06 Ranbaxy Lab Ltd
US20030018061A1 (en) * 2000-01-28 2003-01-23 Kohei Ogawa Novel remedies with the use of beta 3 agonist
ES2328446T5 (es) * 2000-02-04 2014-02-27 Children's Hospital Research Foundation Uso de lipasa ácida lisosomal para tratar la aterosclerosis y enfermedades asociadas
EP1286984A2 (fr) 2000-03-10 2003-03-05 Pharmacia Corporation Procede de preparation de tetrahydrobenzothiepines
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
WO2001068096A2 (fr) * 2000-03-10 2001-09-20 Pharmacia Corporation Polytherapie pour la prophylaxie et le traitement d'etats et de troubles hyperlipidemiques
ATE524163T1 (de) 2000-04-10 2011-09-15 Teva Pharma Stabile pharmazeutische zusammensetzungen enthaltend 7-substituierte-3,5- dihydroxyheptansäuren oder 7-substituierte-3,5- dihydroxyheptensäuren
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
DE10030375A1 (de) * 2000-06-21 2002-01-03 Bayer Ag Verwendung von MTP-Inhibitoren zur Senkung von ppTRL
AU2001284413A1 (en) * 2000-08-30 2002-03-13 Sankyo Company Limited Medicinal compositions for preventing or treating heart failure
JO2654B1 (en) * 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents
US8586094B2 (en) 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
US6936731B2 (en) * 2000-10-05 2005-08-30 TEVA Gyógyszergyár Részvénytársaság Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
JP3737801B2 (ja) * 2000-10-05 2006-01-25 テバ ジョジセルジャール レースベニュタールシャシャーグ プラバスタチンラクトン及びエピプラバスタチンを実質的に含まないプラバスタチンナトリウム、並びにそれを含む組成物
US20050215636A1 (en) * 2000-10-05 2005-09-29 Vilmos Keri Pravastatin sodium substantially free of pravastatin lactone and EPI-pravastatin, and compositions containing same
US20030162829A1 (en) * 2000-10-06 2003-08-28 George Kindness Combination of treatment of cancer utilizing a COX-2 inhibitor and a 3-hydroxy-3-methylglutaryl-coenzyme-a (HMG-CoA) reductase inhibitor
US6534540B2 (en) 2000-10-06 2003-03-18 George Kindness Combination and method of treatment of cancer utilizing a COX-2 inhibitor and a 3-hydroxy-3-methylglutaryl-coenzyme-a (HMG-CoA) reductase inhibitor
JP2002121172A (ja) * 2000-10-16 2002-04-23 Sankyo Co Ltd プラバスタチン又はその薬理上許容される塩の精製方法
JP3236282B1 (ja) * 2000-10-16 2001-12-10 三共株式会社 プラバスタチンを精製する方法
US6916849B2 (en) 2000-10-23 2005-07-12 Sankyo Company, Limited Compositions for improving lipid content in the blood
CA2428204A1 (fr) 2000-11-07 2002-05-16 Sankyo Company, Limited Compositions permettant de reduire la concentration de peroxydes lipidiques
US6777552B2 (en) * 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
JO2409B1 (en) * 2000-11-21 2007-06-17 شركة جانسين فارماسوتيكا ان. في Second-phenyl carboxy amides are useful as lipid-lowering agents
US20030232834A1 (en) * 2001-03-08 2003-12-18 Keller Bradley T Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
PL369268A1 (en) * 2001-03-27 2005-04-18 Ranbaxy Laboratories Limited A stable pharmaceutical composition of pravastatin
JO2390B1 (en) * 2001-04-06 2007-06-17 شركة جانسين فارماسوتيكا ان. في Diphenylcarboxamides act as lipid-lowering agents
ES2258141T3 (es) 2001-04-11 2006-08-16 Bristol-Myers Squibb Company Complejos de aminoacidos de glucosidos c-arilo para el tratamiento de la diabetes y procedimiento.
CN1509180A (zh) * 2001-04-18 2004-06-30 ԭ���ø� 用脂肪族聚胺治疗综合症x的方法
CA2445712A1 (fr) * 2001-05-31 2002-12-05 Cellegy Pharmaceuticals, Inc. Inhibiteurs d'influx calcique active par reserve, et leurs procedes d'utilisation
US20040180087A1 (en) * 2001-06-21 2004-09-16 Boyong Li Stable controlled release pharmaceutical compositions containing pravastatin
WO2003000239A1 (fr) * 2001-06-21 2003-01-03 Andrx Pharmaceuticals, Inc. Compositions pharmaceutiques stables a base de pravastatine
US20040092565A1 (en) * 2001-07-25 2004-05-13 George Kindness Composition and method of sustaining chemotherapeutic effect while reducing dose of chemotherapeutic agent using cox-2 inhibitor and statin
US20040077625A1 (en) * 2001-07-25 2004-04-22 Tremont Samuel J. Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
ATE316146T1 (de) * 2001-09-27 2006-02-15 Biocon Ltd Verfahren zur herstellung von pravastatin- natriumsalz mittels streptomyces flavidovirens dsm 14455
KR100414334B1 (ko) * 2001-09-29 2004-01-07 코바이오텍 (주) 프라바스타틴 나트륨의 생산 방법
US7238671B2 (en) * 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
KR20040054729A (ko) * 2001-10-18 2004-06-25 브리스톨-마이어스 스큅 컴퍼니 인간 글루카곤-유사-펩티드-1 모방체, 및 당뇨병 및 이와관련된 증상의 치료에 있어서 이의 용도
US6740663B2 (en) 2001-11-02 2004-05-25 G.D. Searle, Llc Mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
US6806381B2 (en) * 2001-11-02 2004-10-19 Bristol-Myers Squibb Company Process for the preparation of aniline-derived thyroid receptor ligands
WO2003043624A1 (fr) * 2001-11-16 2003-05-30 Bristol-Myers Squibb Company Inhibiteurs doubles de la proteine de liaison des acides gras des adipocytes et de la proteine de liaison des acides gras des keratinocytes
US6831102B2 (en) * 2001-12-07 2004-12-14 Bristol-Myers Squibb Company Phenyl naphthol ligands for thyroid hormone receptor
AU2002351412B2 (en) 2001-12-21 2010-05-20 Exelixis Patent Company Llc Modulators of LXR
US6696473B2 (en) * 2001-12-21 2004-02-24 X-Ceptor Therapeutics, Inc. Heterocyclic modulators of nuclear receptors
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
AU2003207431A1 (en) 2002-01-17 2003-09-02 Pharmacia Corporation Novel alkyl/aryl hydroxy or keto thiepines.
KR100379075B1 (en) * 2002-03-07 2003-04-08 Jinis Biopharmaceuticals Co Method for producing low cholesterol animal food product and food product therefrom
HUP0500074A3 (en) * 2002-03-18 2005-07-28 Biocon Ltd Bangalore Amorphous hmg-coa reductase inhibitors of desired particle size and process for producing them
US20050089572A1 (en) * 2002-03-22 2005-04-28 Manoj Kumar Controlled release drug delivery system of pravastatin
US20050113577A1 (en) * 2002-04-16 2005-05-26 Karki Shyam B. Solid forms of slats with tyrosine kinase activity
WO2003094845A2 (fr) 2002-05-08 2003-11-20 Bristol-Myers Squibb Company Ligands du recepteur de la thyroide a base de pyridine
PT3072978T (pt) 2002-05-09 2018-10-15 Brigham & Womens Hospital Inc 1l1rl-1 como um marcador de doença cardiovascular
US7672397B2 (en) * 2002-05-14 2010-03-02 Otmar Irscheid Method for producing a transmission signal
US7057046B2 (en) * 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
CA2488498A1 (fr) * 2002-06-10 2003-12-18 Elan Pharma International Limited Formulation de polycosanol nanoparticulaires et nouvelles combinaisons de polycosanol
US20050182106A1 (en) * 2002-07-11 2005-08-18 Sankyo Company, Limited Medicinal composition for mitigating blood lipid or lowering blood homocysteine
BR0313186A (pt) * 2002-07-23 2005-06-21 Nutrinova Gmbh Agente redutor de colesterol proveniente de fibra alimentar e substâncias redutoras de colesterol
US20050182036A1 (en) * 2002-08-02 2005-08-18 Sankyo Company, Limited Medicinal composition containing an HMG-CoA reductase inhibitor
US20050187204A1 (en) * 2002-08-08 2005-08-25 Sankyo Company, Limited Medicinal composition for lowering blood lipid level
UA79300C2 (en) * 2002-08-12 2007-06-11 Janssen Pharmaceutica Nv N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion
JP2006506445A (ja) 2002-08-28 2006-02-23 ホリス − イーデン ファーマスーティカルズ、 インコーポレイテッド 治療処置の方法
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
ATE469645T1 (de) * 2002-10-23 2010-06-15 Bristol Myers Squibb Co Auf glycinnitril basierende hemmer der dipeptidylpeptidase iv
JP2006514100A (ja) * 2002-10-24 2006-04-27 イーノス・ファーマシューティカルス・インコーポレーテッド 徐放性ｌ−アルギニン製剤並びに製造方法および使用方法
US20080145424A1 (en) * 2002-10-24 2008-06-19 Enos Phramaceuticals, Inc. Sustained release L-arginine formulations and methods of manufacture and use
US7098235B2 (en) * 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
US20040110241A1 (en) * 2002-12-06 2004-06-10 Segal Mark S. Materials and methods for monitoring vascular endothelial function
US20040198800A1 (en) * 2002-12-19 2004-10-07 Geoffrey Allan Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
CA2510320C (fr) * 2002-12-20 2012-10-09 St. James Associates Llc/Faber Research Series Particules enrobees destinees a l'administration prolongee d'ingredients pharmaceutiques
EP1961419B1 (fr) 2002-12-20 2010-03-24 Pfizer Products Inc. Formes posologiques comprenant un inhibiteur de CETP et un inhibiteur de HMG-CoA reductase
DE10261061A1 (de) * 2002-12-24 2004-07-15 Nutrinova Nutrition Specialties & Food Ingredients Gmbh Diätetisches Lebensmittel zur positiven Beeinflussung der kardiovaskulären Gesundheit
DE10261067A1 (de) * 2002-12-24 2004-08-05 Nutrinova Nutrition Specialties & Food Ingredients Gmbh Cholesterinsenkendes Mittel, enthaltend eine n-3-Fettsäure
TW200504021A (en) * 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
WO2004066929A2 (fr) * 2003-01-24 2004-08-12 Bristol-Myers Squibb Company Cycloalkyle contenant des ligands anilide pour le recepteur des hormones thyroidiennes
WO2004071431A2 (fr) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Composition et methode de traitement de troubles neurodegeneratifs
EP1452602A1 (fr) * 2003-02-25 2004-09-01 Antibiotic Co., Procédé fermentative de production de pravastatine
US7557143B2 (en) * 2003-04-18 2009-07-07 Bristol-Myers Squibb Company Thyroid receptor ligands
AU2004233693B2 (en) 2003-04-28 2007-07-19 Funahashi, Toru Adiponectin production enhancer
US7772272B2 (en) * 2003-04-28 2010-08-10 Daiichi Sankyo Company, Limited Method for enhancing glucose uptake into warm-blooded animal adipocytes
AR041089A1 (es) 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
US7459474B2 (en) * 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
KR100470078B1 (ko) * 2003-06-12 2005-02-04 씨제이 주식회사 컴팩틴을 프라바스타틴으로 전환할 수 있는 스트렙토마이세스 종(Ｓｔｒｅｐｔｏｍｙｃｅｓ ｓｐ.)ＣＪＰＶ 975652 및 그를 이용한 프라바스타틴의 제조방법
US7368468B2 (en) * 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them
KR20070094805A (ko) * 2003-06-18 2007-09-21 테바 파마슈티컬 인더스트리즈 리미티드 플루바스타틴 나트륨 결정형 ｘｉｖ, ｌｘｘｉｉｉ,ｌｘｘｉｘ, ｌｘｘｘ 및 ｌｘｘｘｖｉｉ, 이의 제조 방법,이를 포함하는 조성물 및 이를 사용하는 방법
JP2007531697A (ja) * 2003-07-11 2007-11-08 プロ−ファーマシューティカルズ，インコーポレイティド 疎水性薬剤のデリバリーのための組成物と方法
CA2532207A1 (fr) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Procedes pharmaceutiques, posologies et formes posologiques pour le traitement de la maladie d'alzheimer
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
US6995183B2 (en) * 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
JP4553899B2 (ja) 2003-08-21 2010-09-29 メルク フロスト カナダ リミテツド カテプシンシステインプロテアーゼ阻害剤
EP1510208A1 (fr) 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Compositions pharmaceutiques comprenant une combinaison de metformine et de statine
CA2537271A1 (fr) * 2003-08-28 2005-03-17 Teva Pharmaceutical Industries, Ltd. Procede de preparation de sels calciques de rosuvastatine
NZ544803A (en) * 2003-08-29 2009-11-27 Kowa Co Method of stabilizing lipid-rich plaque and method of preventing rupture thereof
US20050053664A1 (en) * 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
US20050171207A1 (en) * 2003-09-26 2005-08-04 Myriad Genetics, Incorporated Method and composition for combination treatment of neurodegenerative disorders
CA2540202A1 (fr) * 2003-09-29 2005-04-21 Enos Pharmaceuticals, Inc. Formulations de l'arginine a liberation prolongee, procedes de fabrication et utilisations
US8227434B1 (en) 2003-11-04 2012-07-24 H. Lee Moffitt Cancer Center & Research Institute, Inc. Materials and methods for treating oncological disorders
US7390504B2 (en) * 2003-11-07 2008-06-24 Jj Pharma, Inc. HDL-boosting combination therapy complexes
US20090110760A1 (en) * 2003-11-07 2009-04-30 Toyo Shinyaku Co., Ltd. Lipometabolism improver containing pine bark extract
US7576121B2 (en) * 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7317109B2 (en) * 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7767828B2 (en) * 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
EP1689757B1 (fr) * 2003-11-12 2014-08-27 Phenomix Corporation Composes heterocycliques d'acide boronique
EP1689383B1 (fr) 2003-11-19 2012-10-31 Metabasis Therapeutics, Inc. Nouvelles substances thyromimetiques contenant du phosphore
WO2005051921A1 (fr) * 2003-11-24 2005-06-09 Teva Pharmaceutical Industries Ltd. Sels d'ammonium cristallins de la rosuvastatine
EP1641447B1 (fr) * 2003-11-24 2008-10-29 TEVA Gyógyszergyár Zártkörüen Müködö Részvénytársaság Procede de purification de pravastatine
JP2007512347A (ja) * 2003-11-26 2007-05-17 デューク・ユニバーシティー 緑内障を予防するかまたは治療する方法
CN1277826C (zh) * 2003-12-01 2006-10-04 叶红平 辉伐他汀及其合成方法和以辉伐他汀为原料药的制剂
KR100887264B1 (ko) * 2003-12-02 2009-03-06 테바 파마슈티컬 인더스트리즈 리미티드 로수바스타틴의 특성화를 위한 기준 표준물
KR20060118557A (ko) * 2003-12-17 2006-11-23 다이닛본 스미토모 세이야꾸 가부시끼가이샤 의약 조성물 및 조합물
WO2005062824A2 (fr) 2003-12-23 2005-07-14 Merck & Co., Inc. Composes anti-hypercholesterolemie
US20050159615A1 (en) * 2003-12-24 2005-07-21 Entire Interest. Process for preparation of statins with high syn to anti ratio
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
US20070179166A1 (en) * 2003-12-24 2007-08-02 Valerie Niddam-Hildesheim Process for preparation of statins with high syn to anti ratio
JPWO2005063294A1 (ja) * 2003-12-30 2007-12-13 興和株式会社 γ−セクレターゼ複合体形成阻害剤
US20070161700A1 (en) * 2004-12-28 2007-07-12 Kowa Company, Ltd. Inhibitor for the formation of y-secretase complex
US8163797B2 (en) * 2003-12-31 2012-04-24 Actavis Elizabeth Llc Method of treating with stable pravastatin formulation
TWI252253B (en) * 2004-01-09 2006-04-01 Chinese Petroleum Corp A novel Pseudonocardia sp RMRC PAH4 and a process for bioconverting compactin into pravastatin using the same
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
EP1563837A1 (fr) * 2004-02-03 2005-08-17 Ferrer Internacional, S.A. Compositions hypocholesterolemiques comprenant une statine et un médicament antiflatulent
EP1718146A2 (fr) * 2004-02-13 2006-11-08 Pro-Pharmaceuticals, Inc. Compositions et procedes utilises pour traiter l'acne et la candida
JP4711952B2 (ja) * 2004-02-25 2011-06-29 興和株式会社 Ｒａｃタンパク質の核内移行促進剤及びそのスクリーニング方法
EP1719525B1 (fr) 2004-02-25 2014-12-10 Kowa Company, Ltd. Promoteur de transfert nuclaire pour la proteine cdc42 et methode de criblage pour celle-ci
NZ549721A (en) 2004-03-05 2010-08-27 Univ Pennsylvania Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
US20060211752A1 (en) 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
JP2007529554A (ja) * 2004-03-19 2007-10-25 プロ−ファーマシューティカルズ，インク． 多価リガンド結合糖質ポリマーを用いた組成物、および該組成物による転移腫瘍の標的療法
AU2004317826A1 (en) * 2004-03-30 2005-10-13 Lupin Ltd An improved method for manufacture of 4-hydroxy pyran-2-one derivatives
CN1938012A (zh) * 2004-03-31 2007-03-28 兴和株式会社 外用剂
KR100598326B1 (ko) 2004-04-10 2006-07-10 한미약품 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
AU2005247195A1 (en) * 2004-05-27 2005-12-08 Dexcel Pharma Technologies Ltd Localized controlled absorption of statins in the gastrointestinal tract for achieving high blood levels of statins
US7803838B2 (en) * 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
TW200611704A (en) * 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
US7145040B2 (en) * 2004-07-02 2006-12-05 Bristol-Myers Squibb Co. Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
US7534763B2 (en) 2004-07-02 2009-05-19 Bristol-Myers Squibb Company Sustained release GLP-1 receptor modulators
CA2573848A1 (fr) * 2004-07-12 2006-02-16 Phenomix Corporation Composes cyano contraints
US7179916B2 (en) * 2004-07-13 2007-02-20 Teva Pharmaceutical Industries Ltd. Process for the preparation of rosuvastatin
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
KR100637762B1 (ko) * 2004-07-30 2006-10-23 주식회사 지니스 저콜레스테롤 란을 생산하기 위한 가금류용 사료첨가제 및 이를 이용한 저콜레스테롤 란의 생산방법
US20110217412A1 (en) * 2004-07-30 2011-09-08 Jinis Biopharmaceuticals Co. Cholesterol lowering supplement and low cholesterol egg produced by using the same
WO2006017417A2 (fr) * 2004-08-02 2006-02-16 Pro-Pharmaceuticals, Inc. Compositions et procedes permettant d'ameliorer l'efficacite d'une chimiotherapie a l'aide de cytotoxines microbiennes
US20090042979A1 (en) * 2004-08-06 2009-02-12 Transform Pharmaceuticals Inc. Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
EP1786414A4 (fr) * 2004-08-06 2008-04-09 Transform Pharmaceuticals Inc Nouvelles compositions pharmaceutiques a base de statines et methodes de traitement associees
CA2573316A1 (fr) * 2004-08-06 2006-02-16 Transform Pharmaceuticals, Inc. Nouvelles preparations de fenofibrate et methodes de traitement associees
BRPI0514303A (pt) * 2004-08-11 2008-06-10 Myriad Genetics Inc composição farmacêutica e método para tratar distúrbios neurodegenerativos
WO2006020850A2 (fr) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Composition pharmaceutique et technique de traitement de troubles neurodegeneratifs
WO2006020852A2 (fr) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Composition pharmaceutique et technique de traitement de troubles neurodegeneratifs
US20070244107A1 (en) * 2004-08-25 2007-10-18 Waters M Gerard Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
US20060058261A1 (en) * 2004-09-15 2006-03-16 Andre Aube Chitin derivatives for hyperlipidemia
AR051446A1 (es) * 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
CA2624601C (fr) 2004-10-06 2018-07-03 The Brigham And Women's Hospital, Inc. Pertinence de niveaux obtenus de marqueurs d'inflammation generalisee a la suite d'un traitement
US7517991B2 (en) * 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
KR101021828B1 (ko) * 2004-10-27 2011-03-17 다이이찌 산쿄 가부시키가이샤 2 이상의 치환기를 갖는 벤젠 화합물
US20090196889A1 (en) * 2004-11-22 2009-08-06 Dexcel Pharma Technologies Ltd. Controlled absorption of statins in the intestine
TWI307360B (en) 2004-12-03 2009-03-11 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Process for constructing strain having compactin hydroxylation ability
KR20070085874A (ko) 2004-12-09 2007-08-27 머크 앤드 캄파니 인코포레이티드 에스트로겐 수용체 조절제
TW200619204A (en) * 2004-12-10 2006-06-16 Kowa Co Method for reduction, stabilization and prevention of rupture of lipid rich plaque
WO2006064016A1 (fr) * 2004-12-15 2006-06-22 Solvay Pharmaceuticals Gmbh Compositions pharmaceutiques comprenant des inhibiteurs nep, inhibiteurs du systeme de production de l'endotheline endogene et inhibiteurs de la reductase hmg coa
US7635699B2 (en) * 2004-12-29 2009-12-22 Bristol-Myers Squibb Company Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US7589088B2 (en) * 2004-12-29 2009-09-15 Bristol-Myers Squibb Company Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US20080194548A1 (en) * 2005-01-06 2008-08-14 Forrest Michael J Drug Combination Therapy and Pharmaceutical Compositions for Treating Inflammatory Disorders
US7368458B2 (en) * 2005-01-12 2008-05-06 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006076569A2 (fr) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Heterocycles bicycliques servant de modulateurs aux recepteurs cannabinoides
WO2006076598A2 (fr) * 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Composes heterocycliques bicycliques en tant que modulateurs des recepteurs de canabinoides
US20060160850A1 (en) * 2005-01-18 2006-07-20 Chongqing Sun Bicyclic heterocycles as cannabinoid receptor modulators
JP2008528626A (ja) * 2005-01-31 2008-07-31 マイラン ラボラトリーズ インク． ヒドロキシル化されたネビボロールを含む薬学的組成物
JP2007533663A (ja) * 2005-02-09 2007-11-22 テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ プラバスタチンナトリウムの製造方法
EP1846410B1 (fr) * 2005-02-10 2009-01-21 Bristol-Myers Squibb Company Dihydroquinazolinones utilisees comme modulateurs de la 5ht
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
CA2683975A1 (fr) * 2005-02-22 2006-08-31 Teva Pharmaceutical Industries Ltd. Rosuvastatine, sels de rosuvastatine exempts de son alkylether, procede d'elaboration correspondant
US20070037979A1 (en) * 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
US20070293535A1 (en) * 2005-02-24 2007-12-20 Kowa Company, Ltd. Nuclear Transfer Promoter for Ddc42 Protein and Method of Screening the Dame
US8722734B2 (en) 2005-03-02 2014-05-13 Merck Sharp & Dohme Corp. Composition for inhibition of cathepsin K
CA2603105A1 (fr) * 2005-03-28 2006-10-05 Dexcel Pharma Technologies Ltd. Absorption regulee de statines dans l'intestin
EP2527337A1 (fr) 2005-04-14 2012-11-28 Bristol-Myers Squibb Company Inhibiteurs de la 11-bêta hydroxystéroïde déshydrogénase de type I
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
US7521557B2 (en) 2005-05-20 2009-04-21 Bristol-Myers Squibb Company Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
US7825139B2 (en) * 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US20060275356A1 (en) * 2005-05-25 2006-12-07 Burgess James W Pharmaceutical compositions for treating or preventing coronary artery disease
TW200716679A (en) * 2005-05-26 2007-05-01 Bristol Myers Squibb Co N-terminally modified GLP-1 receptor modulators
KR101310037B1 (ko) 2005-05-31 2013-09-24 밀란 인크. 네비볼롤을 함유하는 조성물
US7629342B2 (en) * 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
US7632837B2 (en) * 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
US7317012B2 (en) * 2005-06-17 2008-01-08 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoind-1 receptor modulators
TW200726765A (en) * 2005-06-17 2007-07-16 Bristol Myers Squibb Co Triazolopyridine cannabinoid receptor 1 antagonists
US20060287342A1 (en) * 2005-06-17 2006-12-21 Mikkilineni Amarendra B Triazolopyrimidine heterocycles as cannabinoid receptor modulators
US7452892B2 (en) * 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
WO2007002563A1 (fr) 2005-06-27 2007-01-04 Exelixis, Inc. Régulateurs de lxr de type imidazole
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
JP2009502959A (ja) * 2005-07-28 2009-01-29 ブリストル−マイヤーズ スクイブ カンパニー セロトニン受容体アゴニストおよびアンタゴニストとしての置換テトラヒドロ−１ｈ−ピリド［４，３，ｂ］インドール
RU2008108078A (ru) * 2005-08-04 2009-09-10 Трансформ Фармасьютикалз, Инк. (Us) Новые препаративные формы, включающие фенофибрат и статин, и соответствующие способы лечения
US7868169B2 (en) * 2005-08-16 2011-01-11 Teva Pharmaceutical Industries, Ltd. Crystalline rosuvastatin intermediate
US7795436B2 (en) * 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
TW200804345A (en) * 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
US20070048351A1 (en) * 2005-09-01 2007-03-01 Prescient Medical, Inc. Drugs coated on a device to treat vulnerable plaque
WO2007030375A2 (fr) * 2005-09-08 2007-03-15 Children's Hospital Medical Center Therapie a base de lipase acide lysosomiale destinee au traitement de la steatose hepatique non alcoolique et de maladies associees
US20080139457A1 (en) * 2005-09-16 2008-06-12 Virginia Commonwealth University Therapeutic compositions comprising chorionic gonadotropins and HMG CoA reductase inhibitors
US8119358B2 (en) * 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
DE102005049293A1 (de) * 2005-10-15 2007-04-26 Bayer Healthcare Ag Kombinationspräparate von Salzen oder o-Acetylsalicylsäure
JP2009511635A (ja) * 2005-10-18 2009-03-19 エージェリオン ファーマシューティカルズ 哺乳動物における高脂血症に関連する障害を治療するための方法
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US8618115B2 (en) * 2005-10-26 2013-12-31 Bristol-Myers Squibb Company Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
EP2487154B1 (fr) 2005-10-31 2013-10-16 Bristol-Myers Squibb Company Inhibiteurs de la dipeptidyl peptidase IV à base amide de bêta-amino de pyrrolidinyle et procédés
WO2007059372A2 (fr) * 2005-11-09 2007-05-24 St. Jude Children's Research Hospital Utilisation de chloroquine en vue de traiter un syndrome metabolique
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
CN101351551A (zh) * 2005-11-29 2009-01-21 协和发酵工业株式会社 新型蛋白质和编码该蛋白质的dna
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US20090018118A1 (en) * 2005-12-29 2009-01-15 Uros Urleb Heterocyclic compounds
EP1976873A2 (fr) * 2006-01-11 2008-10-08 Brystol-Myers Squibb Company Modulateurs de peptides 1 de type glucagon humain et leur utilisation pour traiter le diabète et des états associés
US7553836B2 (en) * 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
US20090069275A1 (en) * 2006-02-17 2009-03-12 Rocca Jose G Low flush niacin formulation
CA2569776A1 (fr) * 2006-02-17 2007-08-17 Kos Life Sciences, Inc. Formulation de niacine provoquant de faibles symptomes de bouffee congestive
US20070238770A1 (en) * 2006-04-05 2007-10-11 Bristol-Myers Squibb Company Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
DK2010528T3 (en) 2006-04-19 2018-01-15 Novartis Ag 6-O-Substituted Benzoxazole and Benzothiazole Compounds and Methods for Inhibiting CSF-1R Signaling
AU2007240313B2 (en) 2006-04-20 2012-02-02 Amgen Inc. GLP-1 compounds
AU2007243282A1 (en) * 2006-04-28 2007-11-08 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of cardiovascular disease
US20070269503A1 (en) * 2006-05-16 2007-11-22 James Walter Burgess Combinations of HMG CoA reductase inhibitors and negatively charged phospholipids and uses thereof
WO2007139589A1 (fr) * 2006-05-26 2007-12-06 Bristol-Myers Squibb Company Modulateurs des récepteurs de glp-1 à libération prolongée
CA2659082A1 (fr) * 2006-06-07 2007-12-21 Tethys Bioscience, Inc. Marqueurs associes a des evenements arterio-vasculaires et procedes d'utilisation de ces marqueurs
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
US20080044326A1 (en) * 2006-07-04 2008-02-21 Esencia Co., Ltd. Sterilizer for baby products
ES2378281T3 (es) * 2006-07-05 2012-04-10 Nycomed Gmbh Combinación de atorvastatina con un inhibidor de fosfodiesterasa 4 para el tratamiento de neumopatías inflamatorias
EP2046119A2 (fr) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Traitement de troubles psychiatriques
US7795291B2 (en) 2006-07-07 2010-09-14 Bristol-Myers Squibb Company Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
EP2057987B1 (fr) 2006-08-30 2015-03-04 Kyushu University, National University Corporation Composition pharmaceutique contenant une nanoparticule de statine encapsulée
US8173629B2 (en) 2006-09-22 2012-05-08 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20080118572A1 (en) * 2006-10-10 2008-05-22 Harold Richard Hellstrom Methods and compositions for reducing the risk of adverse cardiovascular events associated with the administration of artificial blood
WO2008044236A2 (fr) * 2006-10-10 2008-04-17 Dexcel Pharma Technologies Ltd. Libération améliorée de statines dans l'intestin
EP2089355A2 (fr) 2006-11-01 2009-08-19 Brystol-Myers Squibb Company Modulateurs de recepteur de glucocorticoide, d'activite ap-1 et/ou nf- kappa b, et leur utilisation
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
US20080161279A1 (en) * 2006-12-21 2008-07-03 Wisler Gerald L Methods of Treating Obesity
EA016079B1 (ru) 2007-01-10 2012-01-30 Институто Ди Ричерке Ди Биолоджиа Молеколаре П. Анджелетти Спа Амидзамещенные индазолы в качестве ингибиторов поли(adp-рибоза)полимеразы (parp)
ES2431163T3 (es) 2007-03-01 2013-11-25 Novartis Ag Inhibidores de PIM quinasa y métodos para su uso
MX2009009126A (es) * 2007-03-01 2009-10-28 Concourse Health Sciences Llc Isomeros de niacinato de inositol y usos de los mismos.
TW200901959A (en) 2007-03-09 2009-01-16 Indigene Pharmaceuticals Inc Combination of metformin R-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
WO2008112887A1 (fr) * 2007-03-13 2008-09-18 Musc Foundation For Research Development Procédés de traitement du diabète sucré de type 1
AR065809A1 (es) 2007-03-22 2009-07-01 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
TWI407955B (zh) 2007-03-29 2013-09-11 Kowa Co 高脂血症之預防及／或治療劑
WO2008124121A1 (fr) * 2007-04-06 2008-10-16 Scidose, Llc Polythérapie associant des statines et des 1,4-dihydropyridine-3,5-dicarboxydiesters et combinaisons de ceux-ci
US20080249156A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent and glitazones
CA2681449A1 (fr) * 2007-04-09 2008-10-16 Scidose, Llc Combinaisons de statines et d'agent anti-obesite
WO2008130951A1 (fr) 2007-04-17 2008-10-30 Bristol-Myers Squibb Company Inhibiteurs de 11-bêta-hydroxystéroïde déshydrogénase hétérocyclique condensés de type i
BRPI0810409A2 (pt) 2007-04-18 2015-02-18 Thethys Bioscience Inc Biomarcadores relacionados ao diabetes e métodos de uso destes
PE20090696A1 (es) 2007-04-20 2009-06-20 Bristol Myers Squibb Co Formas cristalinas de saxagliptina y procesos para preparar las mismas
ES2425969T3 (es) 2007-04-27 2013-10-18 Kyushu University, National University Corporation Agente para el tratamiento de enfermedades pulmonares
JP2010528023A (ja) * 2007-05-18 2010-08-19 ブリストル−マイヤーズ スクイブ カンパニー Ｓｇｌｔ２阻害剤の結晶構造およびその製造方法
BRPI0812159A2 (pt) 2007-05-21 2017-05-02 Novartis Ag inibidores de csf-1r, composições e métodos de uso
KR20100031528A (ko) 2007-06-01 2010-03-22 더 트러스티즈 오브 프린스턴 유니버시티 숙주세포 대사경로의 조절을 통한 바이러스 감염 치료
DE102007028406A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028407A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028319A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
AU2008266960A1 (en) 2007-06-20 2008-12-24 Merck Sharp & Dohme Corp. Diphenyl substituted alkanes
DE102007028320A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US20090011994A1 (en) * 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
CN101808995A (zh) * 2007-07-27 2010-08-18 百时美施贵宝公司 新颖的葡糖激酶激活剂及其使用方法
US20090076148A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched pravastatin
CA2697551C (fr) * 2007-09-20 2013-03-12 Irm Llc Composes et compositions en tant que modulateurs de l'activite de gpr119
CN101910171A (zh) 2007-11-01 2010-12-08 百时美施贵宝公司 可用作糖皮质激素受体AP-1和/或者NF-κB活性调节剂的非甾类化合物及其用途
US20090163452A1 (en) * 2007-12-20 2009-06-25 Schwartz Janice B Compositions and methods for lowering serum cholesterol
JP5539221B2 (ja) 2007-12-21 2014-07-02 リガンド・ファーマシューティカルズ・インコーポレイテッド 選択的アンドロゲン受容体モジュレーター（ｓａｒｍ）およびその使用
US20090226515A1 (en) * 2008-03-04 2009-09-10 Pharma Pass Ii Llc Statin compositions
US20090226516A1 (en) * 2008-03-04 2009-09-10 Pharma Pass Ii Llc Sartan compositions
WO2009148709A1 (fr) * 2008-04-16 2009-12-10 University Of Utah Research Foundation Ciblage pharmacologique de malformation vasculaire
PE20091928A1 (es) * 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
ES2330184B1 (es) 2008-06-03 2010-07-05 Neuron Biopharma, S.A. Uso de estatinas como anticonvulsivantes, antiepilepticos y neuroprotectores.
EP2138178A1 (fr) 2008-06-28 2009-12-30 Bayer Schering Pharma Aktiengesellschaft Oxazolidinones pour le traitement de maladie pulmonaire obstructive chronique (MPOC) et/ou de l'asthme
EP2161024A1 (fr) 2008-09-05 2010-03-10 Universitätsklinikum Hamburg-Eppendorf Combinaison pour le traitement de cancer
WO2010041619A1 (fr) 2008-10-06 2010-04-15 メルシャン株式会社 Vecteur d'expression pour pseudonocardia autotrophica
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
SG174504A1 (en) 2009-03-27 2011-10-28 Bristol Myers Squibb Co Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors
WO2010114780A1 (fr) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibiteurs de l'activité akt
TW201039815A (en) 2009-04-13 2010-11-16 Resolvyx Pharmaceuticals Inc Compositions and methods for the treatment of inflammation
US8470805B2 (en) * 2009-04-30 2013-06-25 Kaohsiung Medical University Processes for preparing piperazinium salts of KMUP and use thereof
HRP20170194T1 (hr) 2009-05-28 2017-05-19 Exelixis Patent Company Llc Lxr modulatori
WO2011014520A2 (fr) 2009-07-29 2011-02-03 Irm Llc Composés et compositions pouvant servir de modulateurs de l'activité du gpr119
EA201200570A1 (ru) 2009-10-09 2012-11-30 Айрм Ллк Соединения и композиции в качестве модуляторов активности gpr119
JP5099731B1 (ja) 2009-10-14 2012-12-19 メルク・シャープ・アンド・ドーム・コーポレーション ｐ５３活性を増大する置換ピペリジン及びその使用
MX2012005425A (es) 2009-11-13 2012-06-14 Astrazeneca Uk Ltd Formulaciones de metformina de masa reducida.
ES2689107T3 (es) 2009-11-13 2018-11-08 Astrazeneca Ab Formulaciones de tabletas bicapa
CN104825417A (zh) 2009-11-13 2015-08-12 阿斯利康(瑞典)有限公司 立即释放片剂
US8394858B2 (en) 2009-12-03 2013-03-12 Novartis Ag Cyclohexane derivatives and uses thereof
EP2512514B1 (fr) 2009-12-14 2014-11-05 Kyoto University Procédé de criblage permettant d'identifier des composés pour le traitement de la sclérose latérale amyotrophique
TW201201764A (en) 2010-02-01 2012-01-16 Hospital For Sick Children Remote ischemic conditioning for treatment and prevention of restenosis
TWI562775B (en) 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
SG10201908570RA (en) 2010-03-31 2019-11-28 Hospital For Sick Children Use of remote ischemic conditioning to improve outcome after myocardial infarction
TWI621420B (zh) 2010-04-08 2018-04-21 病童醫院 遠距缺血處理於創傷性傷害的用途
WO2011130459A1 (fr) 2010-04-14 2011-10-20 Bristol-Myers Squibb Company Nouveaux activateurs de la glucokinase et méthodes d'utilisation desdits activateurs
US8372877B2 (en) 2010-04-16 2013-02-12 Cumberland Pharmaceuticals Stabilized statin formulations
CA2799708A1 (fr) 2010-05-21 2011-11-24 Pfizer Inc. 2-phenylbenzoylamides
EP2584903B1 (fr) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk
CN107080846A (zh) 2010-07-09 2017-08-22 詹姆斯.特林卡.格林 用于包括瑞格列净的短半衰期药物的组合立即/延迟释放递送系统
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
AU2011285909B2 (en) 2010-08-02 2016-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
EP2606134B1 (fr) 2010-08-17 2019-04-10 Sirna Therapeutics, Inc. Inhibition médiée par des arn interférents de l'expression génique du virus de l'hépatite b (vhb) à l'aide de petits acides nucléiques interférents (pani)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (fr) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
JPWO2012046772A1 (ja) 2010-10-06 2014-02-24 国立大学法人 東京大学 リンパ浮腫予防治療剤
EP3766975A1 (fr) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Inhibition au moyen d'interférence arn d'une expression de gène utilisant des acides nucléiques à petit interférent (sina)
TWI462739B (zh) 2010-11-02 2014-12-01 Univ Kaohsiung Medical Ｓｉｌｄｅｎａｆｉｌ－同族物四級銨哌嗪鹽類之製備及醫療用途
EP2654748B1 (fr) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Dérivés d'indazole utiles en tant qu'inhibiteurs de erk
WO2012085191A1 (fr) 2010-12-23 2012-06-28 Dsm Sinochem Pharmaceuticals Netherlands B.V. Forme cristalline de la pravastatine et son procédé de préparation
IL295438B2 (en) 2011-01-05 2026-05-01 Lexicon Pharmaceuticals Inc Compositions containing and methods for using inhibitors of sodium-glucose cotransporters 1 and 2
ES2618812T3 (es) 2011-01-20 2017-06-22 Merck Sharp & Dohme Corp. Antagonistas del receptor mineralocorticoide
EP2670486B1 (fr) 2011-01-31 2016-04-06 Cadila Healthcare Limited Traitement de la lipodystrophie
WO2012112363A1 (fr) 2011-02-14 2012-08-23 Merck Sharp & Dohme Corp. Inhibiteurs de cystéine protéases, les cathepsines
CA2828343A1 (fr) 2011-03-04 2012-09-13 The Scripps Research Institute Peptides de type edn3 et utilisations associees
AR088728A1 (es) 2011-03-25 2014-07-02 Bristol Myers Squibb Co Moduladores de lxr como prodroga de imidazol
WO2012139495A1 (fr) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. Antagonistes des récepteurs de minéralocorticoïdes
EP2699567A1 (fr) 2011-04-21 2014-02-26 Merck Sharp & Dohme Corp. Inhibiteurs du récepteur du facteur de croissance 1 analogue à l'insuline
EP2765859B1 (fr) 2011-10-13 2017-01-18 Merck Sharp & Dohme Corp. Antagonistes de récepteur des minéralocorticoïdes
WO2013063214A1 (fr) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Nouveaux composés qui sont des inhibiteurs d'erk
KR101466617B1 (ko) 2011-11-17 2014-11-28 한미약품 주식회사 오메가-3 지방산 및 HMG-CoA 환원효소 억제제를 포함하는 안정성이 증가된 경구용 복합 제제
EP2797641B1 (fr) 2011-12-29 2019-07-10 Trustees Of Tufts College Fonctionnalisation de biomatériaux pour commander la régénération et des réponses à une inflammation
AU2013214693B2 (en) 2012-02-02 2017-02-23 Kenneth Gek-Jin OOI Improvements in tear film stability
EP3358013B1 (fr) 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Compositions d'acide nucléique interférent court (sina)
BR112014027952B1 (pt) 2012-05-10 2022-06-21 Bayer Pharma Aktiengesellschaft Anticorpos monoclonais humanos capazes de se ligarem ao fator de coagulação xi, seu uso, composição farmacêutica e medicamento os compreendendo, ácido nucleico que o codifica, bem como vetor
CN104640856B (zh) 2012-05-11 2017-09-15 复位治疗公司 作为隐花色素调节剂的含有咔唑的磺酰胺类
WO2014022195A1 (fr) 2012-08-01 2014-02-06 Tavakoli Zahra Compositions congelées à écoulement libre comprenant un agent thérapeutique
US8729092B2 (en) 2012-09-24 2014-05-20 Terence J. Scallen Rosuvastatin enantiomer compounds
WO2014052619A1 (fr) 2012-09-27 2014-04-03 Irm Llc Dérivés et compositions de pipéridine comme modulateurs de l'activité de gpr119
KR20150060724A (ko) 2012-09-28 2015-06-03 머크 샤프 앤드 돔 코포레이션 Erk 억제제인 신규 화합물
EP2925735B1 (fr) 2012-11-20 2019-03-13 Lexicon Pharmaceuticals, Inc. Inhibiteurs des co-transporteurs de sodium-glucose 1
DK2925888T3 (en) 2012-11-28 2017-12-18 Merck Sharp & Dohme COMPOSITIONS AND METHODS OF CANCER TREATMENT
EP2935263B1 (fr) 2012-12-20 2018-12-05 Merck Sharp & Dohme Corp. Imidazopyridines substituées en tant qu'inhibiteurs d'hdm2
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
EP2968275B1 (fr) 2013-03-15 2017-11-29 Bristol-Myers Squibb Company Modulateurs des lxr
CA2907765C (fr) 2013-03-21 2021-07-06 Eupraxia Pharmaceuticals USA LLC Composition a liberation prolongee injectable et son procede d'utilisation pour traiter une inflammation dans des articulations et la douleur associee a celle-ci
SG11201507496UA (en) 2013-04-17 2015-11-27 Pfizer N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
MY180160A (en) 2013-04-22 2020-11-23 Cadila Healthcare Ltd A novel composition for nonalcoholic fatty liver disease (nafld)
EP3004053B1 (fr) 2013-05-30 2021-03-24 Cadila Healthcare Limited Procédé de préparation de pyrroles présentant des activités hypocholestérolémiques hypolipidémiques
TW201513857A (zh) 2013-07-05 2015-04-16 Cadila Healthcare Ltd 協同性組成物
IN2013MU02470A (fr) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
US9593113B2 (en) 2013-08-22 2017-03-14 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor
WO2015034925A1 (fr) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Polynucléotides circulaires
IN2013MU02905A (fr) 2013-09-06 2015-07-03 Cadila Healthcare Ltd
CA2923272A1 (fr) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Inhibiteurs de proteases a cysteine de type cathepsines
WO2015051479A1 (fr) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Inhibiteurs de cystéine-protéases de type cathepsines
JP6536871B2 (ja) 2013-12-02 2019-07-03 国立大学法人京都大学 Ｆｇｆｒ３病の予防および治療剤ならびにそのスクリーニング方法
WO2015108988A2 (fr) 2014-01-17 2015-07-23 Ligand Pharmaceuticals, Inc. Méthodes et compositions pour moduler les taux d'hormone
WO2015120580A1 (fr) 2014-02-11 2015-08-20 Merck Sharp & Dohme Corp. Inhibiteurs de protéases à cystéine de type cathépsines
TWI690521B (zh) 2014-04-07 2020-04-11 美商同步製藥公司 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
ES2864079T3 (es) 2014-05-30 2021-10-13 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
ES2822561T3 (es) 2014-09-15 2021-05-04 Univ Leland Stanford Junior Direccionamiento a enfermedad por aneurisma modulando las vías de fagocitosis
WO2016055901A1 (fr) 2014-10-08 2016-04-14 Pfizer Inc. Composés d'amide substitué
ES2838925T3 (es) 2015-02-27 2021-07-02 Univ Leland Stanford Junior Terapia de combinación para el tratamiento de la ateroesclerosis
EP3288584A2 (fr) 2015-04-30 2018-03-07 President and Fellows of Harvard College Anticorps anti-ap2 et agents de liaison à l'antigène utilisables en vue du traitement d'affections métaboliques
WO2017064635A2 (fr) 2015-10-14 2017-04-20 Cadila Healthcare Limited Composé pyrrole, compositions et procédé de préparation associé
TW201720427A (zh) 2015-10-27 2017-06-16 優普順藥物股份有限公司 局部麻醉劑之持續釋放調配物
WO2018071283A1 (fr) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Inhibiteurs de kdm5
US20180243263A1 (en) 2016-12-09 2018-08-30 Cadila Healthcare Ltd. Treatment for primary biliary cholangitis
AU2018277083A1 (en) 2017-05-30 2019-12-05 The Board Of Trustees Of The Leland Stanford Junior University Treatment of neuroinflammatory disease
WO2019094311A1 (fr) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
US11098059B2 (en) 2017-11-08 2021-08-24 Merck Sharp & Dohme Corp. PRMT5 inhibitors
JP7356968B2 (ja) 2018-05-08 2023-10-05 国立大学法人 岡山大学 心血管疾患に有用な医薬
EP3824912A4 (fr) 2018-07-19 2022-04-20 Kyoto University Cartilage en forme de plaque dérivé de cellules souches pluripotentes et procédé de production de cartilage en forme de plaque
WO2020016335A1 (fr) 2018-07-19 2020-01-23 Astrazeneca Ab Méthodes de traitement de hfpef au moyen de dapagliflozine et compositions comprenant celle-ci
EP3833668B1 (fr) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Inhibiteurs de prmt5
BR112021002267A8 (pt) 2018-08-07 2023-02-07 Merck Sharp & Dohme Inibidores de prmt5
WO2020033285A1 (fr) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
EP3833667B1 (fr) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Inhibiteurs de prmt5
AU2019346497A1 (en) 2018-09-26 2021-04-08 Lexicon Pharmaceuticals, Inc. Crystalline forms of n-(1 -((2-(dimethylamino)ethyl)amino)-2-m ethyl-1 -oopropan-2-yl)-4-(4-(2-methyl-5- (2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl) phenl)butanamide and methods of their synthesis
JP7224001B2 (ja) 2018-12-21 2023-02-17 国立大学法人京都大学 ルブリシン局在軟骨様組織、その製造方法及びそれを含む関節軟骨損傷治療用組成物
US11248001B2 (en) 2019-01-18 2022-02-15 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
US20220184058A1 (en) 2019-03-13 2022-06-16 National University Corporation Hamamatsu University School Of Medicine Pharmaceutical composition for treating aortic aneurysm
KR20220003554A (ko) 2019-04-19 2022-01-10 리간드 파마슈티칼스 인코포레이티드 화합물의 결정질 형태 및 결정질 형태를 제조하는 방법
MA56036A (fr) 2019-05-27 2022-04-06 Immatics Us Inc Vecteurs viraux et leur utilisation dans une thérapie cellulaire adoptive
EP4076459B1 (fr) 2019-12-17 2026-04-29 Merck Sharp & Dohme LLC Inhibiteurs de prmt5
BR112022012015A2 (pt) 2019-12-17 2022-08-30 Merck Sharp & Dohme Llc Inibidores de prmt5
CA3160153A1 (fr) 2019-12-17 2021-06-24 Michelle Machacek Inhibiteurs de prmt5
EP4076460B1 (fr) 2019-12-17 2026-01-21 Merck Sharp & Dohme LLC Dérivés de 1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidine] en tant qu'inhibiteurs de prmt5 pour le traitement du cancer
EP4108260A4 (fr) 2020-02-21 2024-03-06 JSR Corporation Composition pour soulager l'hypertension pulmonaire, procédé de prédiction du pronostic de l'hypertension pulmonaire, procédé d'aide à la détermination de la gravité de l'hypertension pulmonaire, et procédé d'aide au diagnostic de l'hypertension pulmonaire
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
PT4188389T (pt) 2020-07-27 2025-10-07 Astrazeneca Ab Dapagliflozina para utilização em métodos de tratamento de doença renal crónica
AU2021202643B2 (en) 2020-07-27 2023-02-02 Astrazeneca Ab Methods of treating chronic kidney disease with dapagliflozin
EP4188372A1 (fr) 2020-07-29 2023-06-07 Amryt Pharmaceuticals Inc. Lomitapide destiné à être utilisé dans des méthodes de traitement de l'hyperlipidémie et de l'hypercholestérolémie chez des patients pédiatriques
US20220056411A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
WO2023275715A1 (fr) 2021-06-30 2023-01-05 Pfizer Inc. Métabolites de modulateurs sélectifs du récepteur des androgènes
CN118510504A (zh) 2022-01-26 2024-08-16 阿斯利康(瑞典)有限公司 用于在治疗糖尿病前期或降低发展2型糖尿病的风险中使用的达格列净
JP2026509792A (ja) 2023-03-02 2026-03-25 カルツィムン ビオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング がん及び／又は急性炎症性疾患を診断するための手段及び方法
WO2025147589A1 (fr) 2024-01-05 2025-07-10 Osanni Bio, Inc. Implants, compositions et méthodes de traitement de maladies et de troubles de la rétine
TW202545529A (zh) 2024-02-05 2025-12-01 瑞典商阿斯特捷利康公司 組合療法
TW202602866A (zh) 2024-03-20 2026-01-16 瑞典商阿斯特捷利康公司 Ｐｃｓｋ９抑制劑及其使用方法
TW202602886A (zh) 2024-03-20 2026-01-16 瑞典商阿斯特捷利康公司 Ｐｃｓｋ９抑制劑及其使用方法
TW202539678A (zh) 2024-03-20 2025-10-16 瑞典商阿斯特捷利康公司 Ｐｃｓｋ９抑制劑及其使用方法
WO2025238159A1 (fr) 2024-05-16 2025-11-20 Astrazeneca Ab Polythérapie comprenant de l'azd0780 et de l'ézétimibe

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5612114B2 (fr) * 1974-06-07 1981-03-18
US4137322A (en) * 1976-11-02 1979-01-30 Sankyo Company Limited ML-236B carboxylic acid derivatives and their use as antihyperlipemic agents
JPS5925599B2 (ja) * 1979-02-20 1984-06-19 三共株式会社 新生理活性物質モナコリンｋおよびその製造法
JPS55150898A (en) * 1979-05-11 1980-11-25 Sankyo Co Ltd Preparation of a new physiologically active substance mb-530b
GR69216B (fr) * 1979-06-15 1982-05-07 Merck & Co Inc
US4319039A (en) * 1979-06-15 1982-03-09 Merck & Co., Inc. Preparation of ammonium salt of hypocholesteremic fermentation product
US4294926A (en) * 1979-06-15 1981-10-13 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4342767A (en) * 1980-01-23 1982-08-03 Merck & Co., Inc. Hypocholesteremic fermentation products

Also Published As

Publication number Publication date
ES8300353A1 (es) 1982-11-01
SE8103560L (sv) 1981-12-07
GB2077264B (en) 1984-04-26
US4346227A (en) 1982-08-24
GB2077264A (en) 1981-12-16
NL191738C (nl) 1996-05-03
CA1150170A (fr) 1983-07-19
DE3122499A1 (de) 1981-12-24
US4410629A (en) 1983-10-18
FI71168B (fi) 1986-08-14
NL960028I1 (nl) 1997-01-06
DK149080C (da) 1986-07-28
NL960028I2 (nl) 1997-07-01
FR2483912A1 (fr) 1981-12-11
FI811762L (fi) 1981-12-07
DE3122499C2 (fr) 1987-11-26
DK149080B (da) 1986-01-13
FR2483912B1 (fr) 1985-07-12
IE811257L (en) 1981-12-06
NL8102737A (nl) 1982-01-04
CH655090A5 (de) 1986-03-27
NL191738B (nl) 1996-01-02
US4448979A (en) 1984-05-15
FI71168C (fi) 1986-11-24
ES502827A0 (es) 1982-11-01
IE51270B1 (en) 1986-11-26
ATA256781A (de) 1983-09-15
MX7065E (es) 1987-04-10
IT8167777A0 (it) 1981-06-05
AU549988B2 (en) 1986-02-27
SE453389B (sv) 1988-02-01
DK247081A (da) 1981-12-07
AU7137681A (en) 1981-12-10
IT1144598B (it) 1986-10-29
AT374495B (de) 1984-04-25

Similar Documents

Publication Publication Date Title
FR2483912B1 (fr) Derives hydroxycarboxyles du compose ml-236b, leur procede de preparation et leur application therapeutique
BE892758A (fr) Derives phenylcyclobutyliques, leur procede de preparation et leur application therapeutique
FR2504920B1 (fr) Derives phenylcyclobutyliques, leur procede de preparation et leur application therapeutique
BE890962R (fr) Nouveaux derives du nor-tropane, leur procede de preparation et leur application en therapeutique
BE878723A (fr) Derives de 4-anilinoquinazoline, leur procede de preparation et leur application en therapeutique
BE892270A (fr) Nouveaux derives aminomethyl-5 oxazolidiniques, leur procede de preparation et leur application en therapeutique
FR2511682B1 (fr) Derives de cephalosporine, leur procede de preparation et leur application therapeutique
FR2509310B1 (fr) Nouvelles cephalosporines, leur procede de preparation et leur application en therapeutique
FR2532648B1 (fr) Derives de carbostyrile, leur procede de preparation et leur application en therapeutique
BE881134A (fr) Nouveaux derives du nor-tropane, leur procede de preparation et leur application en therapeutique
BE862785A (fr) Derives de pyrimido(6,1-a)isoquinoleine-2-one, leur procede de preparation et leur application en therapeutique
PT73988B (fr) Procede de preparation de derives de la thieno-pyridinone et leur application therapeutique
IT1209758B (it) E-5-(2-alogenovinil-)-2&#39;deossicitidine, loro metodo di preparazione e loro impiego per il trattamentodi malattie da virus
FR2506306B1 (fr) Nouveaux derives de l&#39;amidinopiperidine, leur procede de preparation et leur application en therapeutique
BE888332A (fr) Composes inhibiteurs de la biosynthese du cholesterol, leur procede de preparatio et de biosynthese du cholesterol. leur procede de preparation et leur application therapeutique,
BE883713A (fr) Nouveau derives de carbostyrile, leur procede de preparation et leur application en therapeutique
BE854133A (fr) 1,3-dihydro-heteroarylspito(isobenzofurannes)et leur procede de preparation et leur application therapeutique
BE866676A (fr) Derives de bisamidine, leur procede de preparation et leur application therapeutique
BE854812A (fr) Benzenesulfonylurees, leur procede de preparation et leur application therapeutique
FR2526798B1 (fr) Derives de peneme, leur procede de preparation et compositions therapeutiques les contenant
FR2514768B1 (fr) Derives de phosphoramide, leur procede de preparation et leur application en therapeutique
PT68267A (fr) Procede de preparation de derives d&#39;oxadiazole-1,2,4 et leur application en therapeutique
FR2516509B1 (fr) Derives benzylideniques, leur preparation et leur application en therapeutique
FR2351098A1 (fr) Derives de l&#39;isothiouree, leur procede de preparation et leur application therapeutique
FR2477142B1 (fr) Nouveaux derives de la nitrosouree, leur procede de preparation et leur application en therapeutique

Legal Events

Date Code Title Description
CCPA Application for a supplementary protection certificate

Free format text: 093C0048

CCPV Grant of a supplementary protection certificate

Free format text: 093C0048, EXPIRES 20040810

RE20 Patent expired

Owner name: SANKYO CY LTD

Effective date: 20010609

CCRE Expiry of a supplementary protection certificate

Free format text: PRODUCT NAME: PRAVASTATINE SODIQUE; NAT. REGISTRATION NO/DATE: 203 IS 216 F3 / 19920929; FIRST REGISTRATION: FR 332 22 9 19980810

Spc suppl protection certif: 93C0048

Filing date: 19930607

Expiry date: 20010609

Extension date: 20040810